• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2020 Fiscal Year Final Research Report

Construction of innovative preemptive medicine for gastrointestinal cancer especially including pancreatic cancer

Research Project

  • PDF
Project/Area Number 18K18464
Research Category

Grant-in-Aid for Challenging Research (Exploratory)

Allocation TypeMulti-year Fund
Review Section Studies on the Super-Aging Society
Research InstitutionKawasaki Medical School

Principal Investigator

NAGASAKA TAKESHI  川崎医科大学, 医学部, 准教授 (30452569)

Co-Investigator(Kenkyū-buntansha) 山口 佳之  川崎医科大学, 医学部, 教授 (10230377)
楳田 祐三  岡山大学, 大学病院, 講師 (10573735)
堅田 洋佑  川崎医科大学, 医学部, 助教 (20716881)
母里 淑子  岡山大学, 大学病院, 助教 (70708081)
Project Period (FY) 2018-06-29 – 2021-03-31
Keywords腫瘍検査学 / 検査・診断システム / 生体情報・計測 / 健康情報
Outline of Final Research Achievements

In the aging society of developed countries, the morbidity of malignant tumors suddenly destroys the "healthy life expectancy". This means, even in a state where one can live independently in a social life, the end of life will come along with the burden close to despair mentally, physically and economically. However, if gastrointestinal cancer can be detected at early phase, could being fully cured.
In this study, we showed that abnormal methylation is a universal alteration regardless of the type of cancer and possible to screen gastrointestinal cancer in general, including pancreatic cancer, by detecting fecal DNA methylation. For high-risk people with malignancy, continuously detecting fecal DNA methylation could predict in the early stage of onset without any abnormalities in other laboratory findings with extremely minimally invasive, thus lading the foundation for innovative preemptive medicine that enables.

Free Research Field

超高齢社会研究

Academic Significance and Societal Importance of the Research Achievements

本研究結果により、メチル化異常が癌種に関係なく、普遍的に認められる変化であることが示唆され、適切なバイオマーカー選択により、大腸癌、IPMN、食道癌、胃癌、膵癌、十二指腸癌、胆管癌といった悪性腫瘍群と非担癌群を選別することが可能であることが示された。これら結果から、担癌高リスク者に対し、極めて低侵襲である便中メチル化DNA検出を継続的に行うことにより、検査所見でも異常のない発症前期に膵癌・消化器癌を診断・予測し、薬剤投与等による化学予防 (Chemoprevention) を可能にする革新的な先制医療 (Preemptive Medicine) の構築が可能となると確信している。

URL: 

Published: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi